Join to access to all OVN content. Join for Free
The Future of KOL Engagement and new strategies that will emerge
MSL role KOL engagement COVID-19 adjustments virtual engagement scientific congresses

The Future of KOL Engagement and new strategies that will emerge


Share This Article


Summary

In this episode, Joan Cannon shares her journey into the MSL role and the operational shifts faced during the COVID-19 pandemic. The conversation covers adjustments in performance metrics, face-to-face interaction guidelines, and virtual engagement with KOLs. Joan provides insights into the evolving landscape of scientific congresses and the essential skills MSLs need post-COVID. She addresses travel hesitancy, meeting settings with HCPs, and offers comprehensive advice for MSLs and leaders navigating the current climate. The episode concludes with reflections on changes since 2020, end-of-year predictions, and the importance of taking mental breaks.

Today we have Joan Cannon, Senior Director Scientific Affairs at Lundbeck. Joan discusses the future of KOL engagement and what changes as well as new strategies will emerge. 

In this episode we discuss:

  • Joan’s background and her current career
  • How she landed her first MSL role
  • Her MSLs and team in the midst of COVID
  • Their current plan for KOL engagement given the travel bans, etc
  • How she handled the lack of facetime
  • What adjustments did they make within their organization regarding metrics
  • What she anticipates the future to look like and the ideas that she and her team are working on to maintain and continue building KOL relationships
  • What new skills are now mandatory for MSLs given the effect of COVID 19
  • Her thoughts on travel hesitancy amongst her team 
  • Her advice for MSLs and MSL Leaders as we look to the future

Click for Source
MSL role, KOL engagement, COVID-19 adjustments, virtual engagement, scientific congresses

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Positioning Yourself to Become an MSL in 2022
Partner Avatar Bridget Rasmusson

Positioning Yourself to Become an MSL in 2022

Article
Job Search Checklist for Aspiring Medical Science Liaisons
Partner Avatar Tom Caravela

Job Search Checklist for Aspiring Medical Science Liaisons

Podcast
The Power of Non Traditional KOL Engagement
Partner Avatar MSL Talk: Tom Caravela, Lindsey Harrer

The Power of Non Traditional KOL Engagement

Podcast
It Can be Lonely in the Life of an MSL
Partner Avatar MSL Talk: Tom Caravela, Trish Gorecki

It Can be Lonely in the Life of an MSL

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Explore OVN